FDA sets August date to review Jazz's fibromyalgia candidate
This article was originally published in Scrip
Executive Summary
The US FDA has scheduled an advisory panel meeting for Jazz Pharmaceuticals' sodium oxybate (JZP-6) for the treatment of fibromyalgia for patients aged 18 years and older – a chronic condition of unknown cause with symptoms of widespread musculoskeletal pain and fatigue . The arthritis advisory committee and the drug safety and risk management advisory committee will discuss the therapy on 20 August.